ArticleThe Journal of biological chemistry2026
Fortilin binds and stabilizes MEF2C, activates it through phosphorylation, and drives transcription of the cell structural and survival protein CTNNA3.
Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fortilin, a 172 amino acid modulator protein that positively regulates survival and growth pathways, is one of the most abundantly expressed proteins in the heart, and its loss leads to lethal heart failure. While fortilin binds and protects catenin alpha-3 (CTNNA3)-a cardiomyocyte structural and survival protein-against degradation, its role in the transcriptional regulation of CTNNA3 has remained unknown. Here, we report that fortilin also promotes CTNNA3 transcription. Mechanistically, we found that fortilin specifically bound to the N-terminal region (amino acids 1-85) of myocyte enhancer factor 2C (MEF2C)-a transcription factor that drives CTNNA3 expression-but not to MEF2A, MEF2B, or MEF2D, as shown by microscale thermophoresis, proximity ligation assay, and in vitro and in vivo coimmunoprecipitation Western blot analyses. Molecular docking and site-directed mutagenesis identified a critical binding interface involving aspartic acid 25 of fortilin, whereby an aspartic acid 25-to-alanine mutation markedly weakened binding to MEF2C. In addition, fortilin protected MEF2C against ubiquitination and proteasomal degradation and promoted MEF2C serine 59 phosphorylation, a modification essential for its transcriptional activity, both in a binding-dependent manner. Loss of fortilin significantly impaired MEF2C binding to nuclear DNA, reduced CTNNA3 promoter-driven luciferase activity in an MEF2C-dependent fashion, and lowered RNA polymerase II occupancy on the CTNNA3 locus. These data suggest that fortilin is a previously unrecognized transcriptional cofactor of MEF2C. By stabilizing MEF2C and promoting its activating phosphorylation, fortilin enhances the transcription of CTNNA3 while simultaneously stabilizing CTNNA3 protein, thereby sustaining CTNNA3 expression and supporting myocardial structural integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.